Martha Neagu Aristide
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Martha Neagu Aristide has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Gladys Morrison-Thiele
AbbVie Inc, North Chicago, IL
19 shared publications - John H. Strickler
Department of Medicine, Duke University, Durham, NC, USA
19 shared publications - Jonathan Eliezer Cohen
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
19 shared publications - Manish R. Sharma
START Center for Cancer Research - Midwest, Grand Rapids, MI, USA
19 shared publications - Michael Burns
AbbVie Inc, North Chicago, IL
19 shared publications - Yasutoshi Kuboki
Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan
19 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Table S1. Representativeness of Study Participants
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Table S1. Representativeness of Study Participants
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S2. Preliminary mean concentration-time profiles for Temab-A conjugate, total antibody, and unconjugated Top1 inhibitor payload in cycle 1 following 3-mg/kg Q3W dosing in patients with GEA.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S2. Preliminary mean concentration-time profiles for Temab-A conjugate, total antibody, and unconjugated Top1 inhibitor payload in cycle 1 following 3-mg/kg Q3W dosing in patients with GEA.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Table S3. Patients with c-Met expression above the median showed a trend toward better clinical outcomes
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Table S3. Patients with c-Met expression above the median showed a trend toward better clinical outcomes
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S4. Patients with focal MET amplification had increased responses to treatment with Temab-A.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S4. Patients with focal MET amplification had increased responses to treatment with Temab-A.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S1. Study design.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S1. Study design.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
A positive correlation was observed between change in ctDNA levels and change in tumor size from baseline. The ctDNA percent change was estimated using somatic variant allele frequencies (74 genes Genomic panel) and genome wide methylation signals (15 Mb methylation panel). The red lines represent molecular response, defined as ≥50% decrease in circulating tumor fraction from baseline. CR, complete response; ctDNA, circulating tumor DNA; PD, progressive disease; PR, partial response; SD, stable disease
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
A positive correlation was observed between change in ctDNA levels and change in tumor size from baseline. The ctDNA percent change was estimated using somatic variant allele frequencies (74 genes Genomic panel) and genome wide methylation signals (15 Mb methylation panel). The red lines represent molecular response, defined as ≥50% decrease in circulating tumor fraction from baseline. CR, complete response; ctDNA, circulating tumor DNA; PD, progressive disease; PR, partial response; SD, stable disease
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Table S2. Cycle 1 pharmacokinetic parameters for Temab-A conjugate and free Top1 inhibitor following 3-mg/kg Q3W dosing of Temab-A in patients with GEA
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Table S2. Cycle 1 pharmacokinetic parameters for Temab-A conjugate and free Top1 inhibitor following 3-mg/kg Q3W dosing of Temab-A in patients with GEA
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S3. Cycle 1 PK (Cmax and AUC) comparisons for Temab-A conjugate and free Top1 inhibitor following 3-mg/kg Q3W dosing of Temab-A in Asian and non-Asian patients with GEA.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Supplementary Figure S3. Cycle 1 PK (Cmax and AUC) comparisons for Temab-A conjugate and free Top1 inhibitor following 3-mg/kg Q3W dosing of Temab-A in Asian and non-Asian patients with GEA.
- Open Access
- 10 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (20) , 1876-1888
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
PURPOSE: The antibody-drug conjugate Temab-A comprises the c-Met–targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier: NCT05029882 ) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion. METHODS: Temab-A was administered intravenously once every 3 weeks as a monotherapy starting at 1.6 mg/kg in dose escalation. In mCRC dose expansion, patients with confirmed BRAF wild-type, microsatellite stable/mismatch repair-proficient mCRC were randomly assigned to 1.6 mg/kg, 2.4 mg/kg, or 3.0 mg/kg Temab-A once every 3 weeks. Primary end points included safety, pharmacokinetics, recommended phase II dose of Temab-A monotherapy, and Temab-A efficacy in patients with mCRC. RESULTS: In total, 57 patients received ≥1 dose of Temab-A in dose escalation; 3.0 mg/kg once every 3 weeks was established as the maximum tolerated dose. Collectively, in dose escalation and dose expansion, 122 patients with mCRC received Temab-A (dose escalation, N = 29; randomized dose optimization expansion, N = 93). All patients experienced ≥1 treatment-emergent adverse event; the most frequent were gastrointestinal (78%) and hematologic (71%) toxicities. Treatment-related discontinuations and deaths were infrequent (10% and 3%, respectively). Across all doses in patients with mCRC, overall response rate was 15.6% (95% CI, 9.6 to 23.2), disease control rate was 74.6% (95% CI, 65.9 to 82.0), and duration of response was 5.9 months (95% CI, 4.1 to 10.5); responses were more frequent at doses of 2.4 mg/kg and 3.0 mg/kg once every 3 weeks. Median progression-free survival was 4.6 months (95% CI: 4.0, 5.4), and median overall survival was 10.4 months (95% CI, 8.9 to 13.1). CONCLUSION: Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.
- 10 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (20) , 1876-1888
Open AccessPhase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
PURPOSE: The antibody-drug conjugate Temab-A comprises the c-Met–targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier: NCT05029882 ) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion. METHODS: Temab-A was administered intravenously once every 3 weeks as a monotherapy starting at 1.6 mg/kg in dose escalation. In mCRC dose expansion, patients with confirmed BRAF wild-type, microsatellite stable/mismatch repair-proficient mCRC were randomly assigned to 1.6 mg/kg, 2.4 mg/kg, or 3.0 mg/kg Temab-A once every 3 weeks. Primary end points included safety, pharmacokinetics, recommended phase II dose of Temab-A monotherapy, and Temab-A efficacy in patients with mCRC. RESULTS: In total, 57 patients received ≥1 dose of Temab-A in dose escalation; 3.0 mg/kg once every 3 weeks was established as the maximum tolerated dose. Collectively, in dose escalation and dose expansion, 122 patients with mCRC received Temab-A (dose escalation, N = 29; randomized dose optimization expansion, N = 93). All patients experienced ≥1 treatment-emergent adverse event; the most frequent were gastrointestinal (78%) and hematologic (71%) toxicities. Treatment-related discontinuations and deaths were infrequent (10% and 3%, respectively). Across all doses in patients with mCRC, overall response rate was 15.6% (95% CI, 9.6 to 23.2), disease control rate was 74.6% (95% CI, 65.9 to 82.0), and duration of response was 5.9 months (95% CI, 4.1 to 10.5); responses were more frequent at doses of 2.4 mg/kg and 3.0 mg/kg once every 3 weeks. Median progression-free survival was 4.6 months (95% CI: 4.0, 5.4), and median overall survival was 10.4 months (95% CI, 8.9 to 13.1). CONCLUSION: Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Purpose:Gastrointestinal tumors, including esophageal and gastric/gastroesophageal junction adenocarcinoma (GEA), have a high mortality rate and present significant treatment challenges. Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel antibody–drug conjugate targeting the c-Met protein (also known as MET protein), has shown encouraging results in patients with advanced GEA.Patients and Methods:This phase I, open-label, multicenter study assessed the safety, efficacy, and pharmacokinetics (PK) of Temab-A monotherapy (3 mg/kg every 3 weeks intravenously) in patients with advanced GEA. Patients ≥18 years of age with advanced/metastatic GEA who had received 1 to 2 prior systemic therapies were included. The primary objectives were the evaluation of safety, PK, and efficacy; efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). c-Met expression and MET amplification were retrospectively assessed.Results:Forty-two patients with advanced GEA were enrolled; the median age was 60 years. The median follow-up duration was 12.6 months. All patients had one or more treatment-emergent adverse events (TEAE), with 88% experiencing grade ≥3 TEAEs. The most common hematologic TEAEs were anemia (67%), nausea (52%), and decreased appetite (36%). The ORR was 29%, the clinical benefit rate was 71%, and the median DOR was 4.2 months. The median PFS was 4 months, and the median OS was 5.8 months. Exploratory biomarker analyses showed ORR enrichment in patients with higher c-Met protein expression and MET focal amplification.Conclusions:Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Purpose:Gastrointestinal tumors, including esophageal and gastric/gastroesophageal junction adenocarcinoma (GEA), have a high mortality rate and present significant treatment challenges. Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel antibody–drug conjugate targeting the c-Met protein (also known as MET protein), has shown encouraging results in patients with advanced GEA.Patients and Methods:This phase I, open-label, multicenter study assessed the safety, efficacy, and pharmacokinetics (PK) of Temab-A monotherapy (3 mg/kg every 3 weeks intravenously) in patients with advanced GEA. Patients ≥18 years of age with advanced/metastatic GEA who had received 1 to 2 prior systemic therapies were included. The primary objectives were the evaluation of safety, PK, and efficacy; efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). c-Met expression and MET amplification were retrospectively assessed.Results:Forty-two patients with advanced GEA were enrolled; the median age was 60 years. The median follow-up duration was 12.6 months. All patients had one or more treatment-emergent adverse events (TEAE), with 88% experiencing grade ≥3 TEAEs. The most common hematologic TEAEs were anemia (67%), nausea (52%), and decreased appetite (36%). The ORR was 29%, the clinical benefit rate was 71%, and the median DOR was 4.2 months. The median PFS was 4 months, and the median OS was 5.8 months. Exploratory biomarker analyses showed ORR enrichment in patients with higher c-Met protein expression and MET focal amplification.Conclusions:Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.